Cancer detection and complications in transperineal prostate biopsy, with antibiotics only when indicated

被引:6
作者
Boeve, Liselotte M. S. [1 ,5 ]
Bloemendal, Floride T. [1 ]
de Bie, Katelijne C. C. [1 ]
van Haarst, Ernst P. [1 ]
Krul, Eveline J. T. [2 ]
de Bruijn, Julia J. [1 ]
Beems, Sophie [3 ]
Vanhommerig, Joost W. [4 ]
Hovius, Marina C. [1 ]
Ruiter, Annebeth E. C. [1 ]
Lagerveld, Brunolf W. [1 ]
van Andel, George [1 ]
机构
[1] OLVG, Dept Urol, Amsterdam, Netherlands
[2] OLVG, Dept Radiol, Amsterdam, Netherlands
[3] OLVG, Dept Value Based Hlth, Amsterdam, Netherlands
[4] OLVG, Dept Res & Epidemiol, Amsterdam, Netherlands
[5] OLVG, Dept Urol, POB 95500, NL-1090 HM Amsterdam, Netherlands
关键词
prostate cancer; perineal prostate biopsy; diagnostic evaluation; complications;
D O I
10.1111/bju.16041
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe the prostate cancer (PCa) detection rate, including clinically significant prostate cancer (csPCa), in a large cohort of patients who underwent transperineal ultrasonography-guided systematic prostate biopsy (TPB-US) using a probe-mounted transperineal access system, with magnetic resonance imaging (MRI) cognitive fusion in case of a Prostate Imaging-Reporting and Data System grade 3-5 lesion, under local anaesthesia in an outpatient setting. Additionally, to compare the incidence of procedure-related complications with a cohort of patients undergoing transrectal ultrasonographyguided (TRB-US) and transrectal MRI-guided biopsies (TRB-MRI). Patients and Methods This was an observational cohort study in men who underwent TPB-US prostate biopsy in a large teaching hospital. For each participant, prostate-specific antigen level, clinical tumour stage, prostate volume, MRI parameters, number of (targeted) prostate biopsies, biopsy International Society of Uropathology (ISUP) grade and procedure-related complications were assessed. csPCa was defined as ISUP grade >= 2. Antibiotic prophylaxis was only given in those with an increased risk of urinary tract infection. Results A total of 1288 TPB-US procedures were evaluated. The overall detection rate for PCa in biopsy-naive patients was 73%, and for csPCa it was 63%. The incidence of hospitalization was 1% in TPB-US (13/1288), compared to 4% in TRB-US (8/ 214) and 3% in TRB-MRI (7/219; P = 0.002). Conclusions Contemporary combined systematic and target TPB-US with MRI cognitive fusion is easy to perform in an outpatient setting, with a high detection rate of csPCa and a low incidence of procedure-related complications.
引用
收藏
页码:397 / 403
页数:7
相关论文
共 24 条
  • [1] MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
    Ahdoot, Michael
    Wilbur, Andrew R.
    Reese, Sarah E.
    Lebastchi, Amir H.
    Mehralivand, Sherif
    Gomella, Patrick T.
    Bloom, Jonathan
    Gurram, Sandeep
    Siddiqui, Minhaj
    Pinsky, Paul
    Parnes, Howard
    Linehan, W. Marston
    Merino, Maria
    Choyke, Peter L.
    Shih, Joanna H.
    Turkbey, Baris
    Wood, Bradford J.
    Pinto, Peter A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10) : 917 - 928
  • [2] Castellani D, 2022, J UROLOGY, V207, P25, DOI 10.1097/JU.0000000000002251
  • [3] Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology
    Chehab, Monzer A.
    Thakor, Avnesh S.
    Tulin-Silver, Sheryl
    Connolly, Bairbre L.
    Cahill, Anne Marie
    Ward, Thomas J.
    Padia, Siddharth A.
    Kohi, Maureen P.
    Midia, Mehran
    Chaudry, Gulraiz
    Gemmete, Joseph J.
    Mitchell, Jason W.
    Brody, Lynn
    Crowley, John J.
    Heran, Manraj K. S.
    Weinstein, Jeffrey L.
    Nikolic, Boris
    Dariushnia, Sean R.
    Tam, Alda L.
    Venkatesan, Aradhana M.
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 29 (11) : 1483 - 1501
  • [4] Detection of clinically significant cancer in the anterior prostate by transperineal biopsy
    Cowan, Tim
    Baker, Emily
    McCray, Gabriella
    Reeves, Fairleigh
    Houlihan, Kimberley
    Johns-Putra, Lydia
    [J]. BJU INTERNATIONAL, 2020, 126 : 33 - 37
  • [5] de Greeff SC., 2022, NETHMAP MARAN 2022 C, P116
  • [6] Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer
    Drost, Frank-Jan H.
    Osses, Daniel F.
    Nieboer, Daan
    Steyerberg, Ewout W.
    Bangma, Chris H.
    Roobol, Monique J.
    Schoots, Ivo G.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (04):
  • [7] A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
    Epstein, Jonathan I.
    Zelefsky, Michael J.
    Sjoberg, Daniel D.
    Nelson, Joel B.
    Egevad, Lars
    Magi-Galluzzi, Cristina
    Vickers, Andrew J.
    Parwani, Anil V.
    Reuter, Victor E.
    Fine, Samson W.
    Eastham, James A.
    Wiklund, Peter
    Han, Misop
    Reddy, Chandana A.
    Ciezki, Jay P.
    Nyberg, Tommy
    Klein, Eric A.
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 428 - 435
  • [8] Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia
    Immerzeel, Jos
    Israel, Bas
    Bomers, Joyce
    Schoots, Ivo G.
    Van Basten, Jean-Paul
    Kurth, Karl-Heinz
    de Reijke, Theo
    Sedelaar, Michiel
    Debruyne, Frans
    Barentsz, Jelle
    [J]. EUROPEAN UROLOGY, 2022, 81 (01) : 110 - 117
  • [9] MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
    Kasivisvanathan, V
    Rannikko, A. S.
    Borghi, M.
    Panebianco, V
    Mynderse, L. A.
    Vaarala, M. H.
    Briganti, A.
    Budaus, L.
    Hellawell, G.
    Hindley, R. G.
    Roobol, M. J.
    Eggener, S.
    Ghei, M.
    Villers, A.
    Bladou, F.
    Villeirs, G. M.
    Virdi, J.
    Boxler, S.
    Robert, G.
    Singh, P. B.
    Venderink, W.
    Hadaschik, B. A.
    Ruffion, A.
    Hu, J. C.
    Margolis, D.
    Crouzet, S.
    Klotz, L.
    Taneja, S. S.
    Pinto, P.
    Gill, I
    Allen, C.
    Giganti, F.
    Freeman, A.
    Morris, S.
    Punwani, S.
    Williams, N. R.
    Brew-Graves, C.
    Deeks, J.
    Takwoingi, Y.
    Emberton, M.
    Moore, C. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) : 1767 - 1777
  • [10] Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
    Kocarnik, Jonathan M.
    Compton, Kelly
    Dean, Frances E.
    Fu, Weijia
    Gaw, Brian L.
    Harvey, James D.
    Henrikson, Hannah Jacqueline
    Lu, Dan
    Pennini, Alyssa
    Xu, Rixing
    Ababneh, Emad
    Abbasi-Kangevari, Mohsen
    Abbastabar, Hedayat
    Abd-Elsalam, Sherief M.
    Abdoli, Amir
    Abedi, Aidin
    Abidi, Hassan
    Abolhassani, Hassan
    Adedeji, Isaac Akinkunmi
    Adnani, Qorinah Estiningtyas Sakilah
    Advani, Shailesh M.
    Afzal, Muhammad Sohail
    Aghaali, Mohammad
    Ahinkorah, Bright Opoku
    Ahmad, Sajjad
    Ahmad, Tauseef
    Ahmadi, Ali
    Ahmadi, Sepideh
    Rashid, Tarik Ahmed
    Salih, Yusra Ahmed
    Akalu, Gizachew Taddesse
    Aklilu, Addis
    Akram, Tayyaba
    Akunna, Chisom Joyqueenet
    Al Hamad, Hanadi
    Alahdab, Fares
    Al-Aly, Ziyad
    Ali, Saqib
    Alimohamadi, Yousef
    Alipour, Vahid
    Aljunid, Syed Mohamed
    Alkhayyat, Motasem
    Almasi-Hashiani, Amir
    Almasri, Nihad A.
    Al-Maweri, Sadeq Ali Ali
    Almustanyir, Sami
    Alonso, Nivaldo
    Alvis-Guzman, Nelson
    Amu, Hubert
    Anbesu, Etsay Woldu
    [J]. JAMA ONCOLOGY, 2022, 8 (03) : 420 - 444